Overview


According to FutureWise analysis the market for Biobetters is expected to register a CAGR of 8.02% from 2023-2031.

Recombinant protein medications from the same class as an existing biopharmaceutical are referred to as "biobetters," or "biosuperiors," and are therefore superior to the original. It is not entirely a novel medication, nor is it a generic version of an already available medication. It is a biological product that was created with the goal of increasing clinical efficacy, improving tolerability, and decreasing the frequency of dosing and administration. The improved versions of the current biologics are known as biobetters. It is neither a completely new drug nor a generic version of an established one. It is a biological substance made to lessen dosing/administration frequency, improve tolerance, and boost clinical efficacy. Due to the pressing need to develop a way to improve the safety and efficiency of biologics, biobetters are a formidable competitor to biosimilars. Growing investments in the creation of therapeutic drugs with improved efficacy and safety profiles for autoimmune diseases and cancer have influenced the growth patterns of the biobetters industry. In recent years, concentrated efforts have been made to lessen the financial burden of chronic diseases. The growing variety of monoclonal antibodies has also positively impacted the market for biobetters. The prevalence of chronic disorders such chronic renal disease and anaemia brought on by chemotherapy is rising, which has also contributed to the market's rise. Additionally, patients typically finish their entire treatment cycle because of the moderate dose frequency. As a result, the Biobetters market is anticipated to expand rapidly in the future. An array of biophysical and biochemical techniques have surfaced recently, spurring the development of the biobetters market and giving it a significant boost.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Biobetters Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Biobetters Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • F.Hoffmann-La Roche AG
  • MerckCo. Inc.
  • Sanofi SA
  • Servier
  • Porton Biopharma Limited
  • Eli Lily and Company
  • Novo Nordisk A/S
  • Biogen Inc.
  • CSL Behring GmbH
  • Teva Pharmaceutical Industries Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Erythropoietin biobetters
  • G-CSF biobetters
  • Interferon biobetter
  • Insulin biobetters
  • Monoclonal antibodies biobetters
  • Anti-hemophilic factor
  • Interferon biobetter

By Indication

  • Diabetes
  • Cancer
  • Renal disease
  • Neurodegenerative disease
  • Genetic disorders (hemophilia)

By Route of Administration

  • Subcutaneous
  • Intravenous

By Distribution Channel

  • Hospitals pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa


  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Biobetters Market By Drug Class, By Indication, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping-product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Biobetters Market Variables, Trends and Scope
    •          1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Biobetters Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Biobetters Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Biobetters Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Erythropoietin biobetters
        2. G-CSF biobetters
        3. Interferon biobetter
        4. Insulin biobetters
        5. Monoclonal antibodies biobetters
        6. Anti-hemophilic factor
        7. Interferon biobetter

  • 8.   Biobetters Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Diabetes
        2. Cancer
        3. Renal disease
        4. Neurodegenerative disease
        5. Genetic disorders (hemophilia)

  • 9.   Biobetters Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Subcutaneous
        2. Intravenous

  • 10.   Biobetters Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals pharmacies
        2. Retail pharmacies
        3. Online pharmacies

  • 11.   North America Biobetters Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Biobetters Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Biobetters Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Biobetters Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. F.Hoffmann-La Roche AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. MerckCo. Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Sanofi SA
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Servier
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Porton Biopharma Limited
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Eli Lily and Company
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Novo Nordisk A/S
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Biogen Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. CSL Behring GmbH
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Teva Pharmaceutical Industries Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients